Benralizumab (Fasenra®) Autoinjector under High Tech Drug Arrangements.
Benralizumab (Fasenra®) is indicated for use as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||31/03/2020|
|Rapid review completed||28/04/2020|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that benralizumab not be considered for reimbursement under high tech drug arrangements at the submitted price*.|
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.